MicroSalt (LSE:SALT) delivered an upbeat trading update, posting unaudited sales of $1.66 million for the first ten months of 2025—exceeding initial expectations. The company has deepened its relationship with a major North American customer, forecasting material sales increases in 2026 and 2027, and has signed a non-binding term sheet for a Joint Development Agreement aimed at lowering sodium levels in food products. MicroSalt also entered a strategic partnership with plant-based producer Daiya Foods, further strengthening its growth outlook for the years ahead. Together, these initiatives highlight the company’s strategy to scale sustainably while promoting healthier food solutions and enhancing long-term investor value.
Despite the operational momentum, MicroSalt’s outlook continues to be weighed down by significant financial weaknesses, including ongoing losses and negative equity. Technical indicators also reflect persistent bearish pressure, with shares trading below major moving averages and flirting with oversold conditions. A negative P/E ratio and lack of dividend yield add to valuation concerns.
More about MicroSalt plc
MicroSalt is an innovator in the global salt market, offering a patented, full-flavour, low-sodium alternative designed for food manufacturers and consumers. Its technology uses micron-sized salt particles to deliver the same taste impact with about 50% less sodium, addressing a major global health challenge. Founded in 2018, the company holds a strong intellectual property portfolio—including a U.S. patent and 14 pending applications worldwide—positioning it for expansion as demand for healthier sodium solutions grows.
Leave a Reply